uniQure Inks $2 Billion Licensing Deal With CSL Behring
In exchange for up to $2.1 billion plus royalties on sales, uniQure (NASDAQ: QURE) licensed the global commercialization rights for its hemophilia B gene therapy, etranacogene dezaparvovec, to CSL Behring (OTC: CSLLY) on Wednesday.
Etranacogene dezaparvovec is a clinical-stage gene therapy that could significantly disrupt hemophilia B treatment. A hereditary disorder, hemophilia B prevents patients from producing adequate levels of blood clotting factor IX, resulting in significant risk of uncontrolled bleeding events and requiring a lifetime of regular infusions.
Image source: Getty Images.
Source Fool.com
